Niraparib Dosing for mCRPC DNA-Repair Anomalies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic castration-resistant prostate cancer (mCRPC) are ineffective for patients with biallelic DNA-repair anomalies, particularly those who have progressed beyond initial therapies and have advanced disease with significant visceral involvement, offering limited survival benefits and quality of life improvements.
Innovation Solution
Administering a once-daily oral dose of 300 mg niraparib to patients with biallelic DNA-repair anomalies, including BRCA and non-BRCA mutations, who have received prior taxane-based chemotherapy and androgen receptor-targeted therapy, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based chemotherapy is used in molecularly unselected prostate cancer patients, then some treatment effect may be achieved, but significant toxicities occur and results are limited
Solution Approach 1:
The patent applies local quality by targeting treatment specifically to patients with DNA-repair anomalies (BRCA1, BRCA2, or other DNA repair gene mutations) rather than treating all prostate cancer patients uniformly. This biomarker-selected approach concentrates the therapeutic effect on the specific molecular subtype that will respond, while avoiding unnecessary toxicities in patients who would not benefit from platinum-based chemotherapy.
Solution Approach 2:
The patent changes the parameter of patient selection from molecularly unselected to molecularly selected based on DNA-repair anomaly status. This parameter change transforms the treatment approach from a blanket chemotherapy regimen to a precision medicine strategy where treatment is administered only to patients whose tumors have the specific molecular characteristics (DNA-repair defects) that make them susceptible to the therapy.
2Reliability
If existing treatments are used for heavily pre-treated patients with advanced disease, then some disease control may be achieved, but survival benefits and quality of life improvements are limited
Solution Approach 1:
The patent applies preliminary action by identifying and selecting patients with DNA-repair anomalies before administering platinum-based chemotherapy. This preliminary molecular characterization ensures that only patients with the appropriate biomarker profile receive the intensive treatment, thereby maximizing the likelihood of achieving survival benefits and delaying disease progression in the most responsive patient population.
Solution Approach 2:
The patent changes the selection parameter from clinical history alone to a combination of clinical history and molecular biomarker status. This parameter change enables the identification of heavily pre-treated patients who, despite their treatment history, still harbor DNA-repair anomalies and therefore remain candidates for platinum-based chemotherapy with potential survival benefit.
3Productivity
If broad-spectrum chemotherapy is used without molecular selection, then all patients receive treatment, but treatment efficacy is limited due to lack of molecular targeting
Solution Approach 1:
The patent applies local quality by concentrating treatment resources on the specific molecular subtype of prostate cancer characterized by DNA-repair anomalies. Rather than administering chemotherapy to all patients uniformly, the treatment is localized to those with BRCA1, BRCA2, or other DNA repair gene mutations, thereby maximizing treatment efficiency and response rate within the targeted population.
Solution Approach 2:
The patent changes the patient selection parameter from non-molecular to molecular-based, specifically identifying patients with DNA-repair anomalies. This parameter transformation enables precise matching of platinum-based chemotherapy to the molecular characteristics of the tumor, dramatically improving both treatment efficiency and response rate compared to unselected chemotherapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment regimen with niraparib significantly improves median overall survival, radiographic progression-free survival, objective response rate, and time to symptomatic skeletal events, providing a stable to improved Health-Related Quality of Life for patients with mCRPC, particularly those with BRCA DNA-repair anomalies.
Implementation Method 1
Niraparib is an orally available, highly selective poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. PARPs are enzymes responsible for repair of DNA single-strand breaks (SSBs) through a process called base excision repair. PARP inhibition leads to an accumulation of unrepaired SSBs, which result in stalling and collapse of replication forks and, consequently, to double-stranded breaks (DSBs).
Data Source
AI summary
The present invention relates to a method of improving the efficacy of treatment of line 2+ metastatic castration-resistant prostate cancer (mCRPC) with biallelic DNA-repair anomalies in a male human, wherein said biallelic DNA-repair anomalies are selected from: i) BRCA (BRCA1, BRCA2, or a combination thereof), ii) non-BRCA (ATM, FANCA, PALB2, CHEK2, BRIP1, HDAC2, or any combination thereof): or iii) any combination thereof; wherein the male human has received prior taxane-based chemotherapy and androgen receptor (AR)-targeted therapy; said method of improving the efficacy of treatment comprising administering to said male human a once-daily oral dosing of 300 mg niraparib.